73 related articles for article (PubMed ID: 30644322)
1. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
[TBL] [Abstract][Full Text] [Related]
2. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.
Gao J; Zhou J; Zhang M; Zhang Y; Zeng Y; Li S; Xu K; Yao R
Mol Cell Biochem; 2024 Apr; 479(4):843-857. PubMed ID: 37204666
[TBL] [Abstract][Full Text] [Related]
3. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
[TBL] [Abstract][Full Text] [Related]
4. Targeting the NF-κB Pathway as a Combination Therapy for Advanced Thyroid Cancer.
Pozdeyev N; Berlinberg A; Zhou Q; Wuensch K; Shibata H; Wood WM; Haugen BR
PLoS One; 2015; 10(8):e0134901. PubMed ID: 26263379
[TBL] [Abstract][Full Text] [Related]
5. Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma.
Chen G; Gao X; Jia X; Wang Y; Xu L; Yu D; Chang S; Deng H; Hu K; Wang G; Li B; Xu Z; Lu Y; Wang H; Zhang T; Song D; Yang G; Wu X; Zhu H; Zhu W; Shi J
Haematologica; 2024 Apr; 109(4):1206-1219. PubMed ID: 37767568
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Insights into the Generation and Transduction of Hedgehog Signaling.
Qi X; Li X
Trends Biochem Sci; 2020 May; 45(5):397-410. PubMed ID: 32311334
[TBL] [Abstract][Full Text] [Related]
7. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.
Ang DA; Carter JM; Deka K; Tan JHL; Zhou J; Chen Q; Chng WJ; Harmston N; Li Y
Nat Commun; 2024 Mar; 15(1):2513. PubMed ID: 38514625
[TBL] [Abstract][Full Text] [Related]
8. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Zhu Y; Jian X; Chen S; An G; Jiang D; Yang Q; Zhang J; Hu J; Qiu Y; Feng X; Guo J; Chen X; Li Z; Zhou R; Hu C; He N; Shi F; Huang S; Liu H; Li X; Xie L; Zhu Y; Zhao L; Jiang Y; Li J; Wang J; Qiu L; Chen X; Jia W; He Y; Zhou W
Cell Metab; 2024 Jan; 36(1):159-175.e8. PubMed ID: 38113887
[TBL] [Abstract][Full Text] [Related]
9. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
Stadtmauer EA; Pasquini MC; Blackwell B; Hari P; Bashey A; Devine S; Efebera Y; Ganguly S; Gasparetto C; Geller N; Horowitz MM; Koreth J; Knust K; Landau H; Brunstein C; McCarthy P; Nelson C; Qazilbash MH; Shah N; Vesole DH; Vij R; Vogl DT; Giralt S; Somlo G; Krishnan A
J Clin Oncol; 2019 Mar; 37(7):589-597. PubMed ID: 30653422
[TBL] [Abstract][Full Text] [Related]
10. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Terpos E; Katodritou E; Symeonidis A; Zagouri F; Gerofotis A; Christopoulou G; Gavriatopoulou M; Christoulas D; Ntanasis-Stathopoulos I; Kourakli A; Konstantinidou P; Kastritis E; Dimopoulos MA
Int J Cancer; 2019 Jul; 145(2):559-568. PubMed ID: 30650184
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance.
Lee H; Duggan P; Neri P; Tay J; Jimenez-Zepeda VH
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019007. PubMed ID: 30671213
[TBL] [Abstract][Full Text] [Related]
12. Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma.
Lê GN; Bones J; Coyne M; Bazou D; Dowling P; O'Gorman P; Larkin AM
Mol Omics; 2019 Feb; 15(1):7-20. PubMed ID: 30652172
[TBL] [Abstract][Full Text] [Related]
13. Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency.
Li Z; Wu J; Chavez L; Hoh R; Deeks SG; Pillai SK; Zhou Q
PLoS Pathog; 2019 Jan; 15(1):e1007498. PubMed ID: 30645648
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and safety of real-world use of pomalidomide in patients with relapsed/refractory multiple myeloma.
Usami E; Kimura M; Takenaka S; Iwai M; Teramachi H; Yoshimura T
Mol Clin Oncol; 2019 Feb; 10(2):293-298. PubMed ID: 30680210
[TBL] [Abstract][Full Text] [Related]
15. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Kothari S; Hillengass J; McCarthy PL; Holstein SA
Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
Htut M
Curr Hematol Malig Rep; 2019 Feb; 14(1):1-10. PubMed ID: 30666505
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E; Gavriatopoulou M; Roussou M; Bagratuni T; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Dialoupi I; Ntanasis-Stathopoulos I; Spyropoulou-Vlachou M; Psimenou E; Gakiopoulou H; Marinaki S; Papadopoulou E; Ntalianis A; Terpos E; Dimopoulos MA
Amyloid; 2018 Dec; 25(4):234-241. PubMed ID: 30663408
[TBL] [Abstract][Full Text] [Related]
18. PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
Muz B; Buggio M; Azab F; de la Puente P; Fiala M; Padval MV; Weaver DT; Pachter JA; Vij R; Azab AK
Haematologica; 2019 Jul; 104(7):e310-e313. PubMed ID: 30655367
[No Abstract] [Full Text] [Related]
19. Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis.
Huang X; Fu C; Chen L; Chen W; Ren G; Guo J; Zhao L; Zeng C; Zhang H; Gong D; Ren Q; Liu Z
Am J Hematol; 2019 Apr; 94(4):E101-E104. PubMed ID: 30652338
[No Abstract] [Full Text] [Related]
20. Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor.
Maeno S; Koh S; Ichii M; Oie Y; Nishida K; Kanakura Y
Ann Hematol; 2019 Mar; 98(3):793-795. PubMed ID: 30645676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
